This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bryan, G. T. Search for Related Content PubMed Articles by Bryan, G. T.

The Pathogenesis of Experimental Bladder Cancer¹

Division of Clinical Oncology, Department of Human Oncology, University of Wisconsin Center for Health Sciences, Madison, Wisconsin 53706

The pathogenesis of signal morphological lesions of the urinary bladder induced in several species following administration of N-butyl-N-(4-hydroxybutyl)nitrosamine, bracken fern, or N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide is presented. Incidences of bladder neoplasia exceeding 80% were generated in the rat by each compound. Bladder neoplasia was induced in the following species by each substance: by N-butyl-N-(4-hydroxybutyl)nitrosamine in the mouse, hamster, guinea pig, and dog; by bracken fern in the guinea pig, mouse, and cow; and by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in mouse, hamster, and dog. The guinea pig appeared resistant to the bladder oncogenicity of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Different species displayed a gradient of bladder neoplastic responsiveness. Hyperplasia was a consistent early lesion and was usually focal. Early hyperplastic lesions regressed following removal of the carcinogenic stimulus, but later lesions appeared to be irreversible. These animal systems appear useful in providing opportunities for investigations relevant to human bladder cancer.

¹ Supported in part by Grants CA 10017, CA 11946, and CA 14520 from the National Cancer Institute and Grants CA 14523, CA 14524, and CA 17449 from the National Cancer Institute, through the National Bladder Cancer Project. Presented at the National Bladder Cancer Conference, November 28 to December 1, 1976, Miami Beach, Fla.

² To whom requests for reprints should be addressed, at Department of Human Oncology, University of Wisconsin, Center for Health Sciences, 1300 University Avenue, Madison, Wis. 53706.